Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer

Mairead Mcnamara, T Walter, A Horgan, E McKeever, T Min, M McNamara, D Hedley, S Serra, M Krzyzanowska, EX Chen, H Mackay, R Feld, M Moore, J. Knox

    Research output: Contribution to conferencePoster


    Background: Chemotherapy is effective in metastatic or unresectable biliary tract cancer (BTC). The benefits of second-line chemotherapy (CT2) are unclear. Methods: We retrospectively studied all patients (pts) receiving at least one cycle of chemotherapy for advanced BTC at our institution between 1991 and 2011. We analyzed pt and chemotherapy characteristics (type of regimen; tumor response; time to progression (TTP); and overall survival (OS)). The objectives were: 1) to characterize pts eligible for CT2; 2) to evaluate the efficacy of CT2. Results: 367, 89 (24%), and 24 (6%) pts received CT1, CT2, and CT3, respectively. Primary tumor location was the gallbladder (30%), intraphepatic (16%), perihilar (20%), distal common bile duct (20%), and ampulla of Vater (14%). 88% had a baseline performance status of 0-1 prior to CT1. The regimen and efficacy data of CT1 and CT2 are presented in the Table. On univariate analysis females (p=0.002) and pts with TTP >6 months on CT1 (p=0.016) were the only variables associated with receiving CT2. The only factor associated with disease control (objective response+ stable disease) on CT2 was the regimen type (75% with a doublet versus 46% with monotherapy, p=0.03). Conclusions: Among patients with advanced BTC treated with chemotherapy, less than 25% received CT2; but responses were seen and were surprisingly high even in this selected population. Pts with a longer TTP on CT1 were more likely to be offered CT2. Better disease control with CT2 occurs with a doublet than single agent, however clearly more effective therapies must be found. Updated data will be presented.
    Original languageEnglish
    Publication statusPublished - 2012
    EventASCO 2012 Gastrointestinal Cancers Symposium -
    Duration: 1 Jan 1824 → …


    ConferenceASCO 2012 Gastrointestinal Cancers Symposium
    Period1/01/24 → …


    Dive into the research topics of 'Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer'. Together they form a unique fingerprint.

    Cite this